reports
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
- Jean Danjou
- Jean Danjou
- Martial Descoutures
- Martial Descoutures
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Thera...
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers: No dose limiting toxicity reached to date, enabling recruitment of a third patient cohortGNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset of patients, warrant...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combin...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, positionnant cette combinaison innovante comme une nouvelle approche thérapeutique potentielle pour les cancers difficiles à traiter : Pas de toxicité dose-limitante observée à ce jour, permettant la poursuite du recrutement d’une troisième cohorte de patientsLa combinaison GNS561 + MEKi a démontré...
- Carole Braudeau
- Carole Braudeau
Disposal of 9 real estate assets in Belgium
Disposal of 9 real estate assets in Belgium Press releaseDecember 3rd, 2025 Disposal of 9 real estate assets in Belgium Paris, December 3rd, 2025 - Clariane (CLARI.PA - ISIN FR0010386334) today announces that it has completed the sale of a real estate portfolio in Belgium to Care Property Invest. This portfolio comprises the buildings of 9 nursing and care homes developed between 2010 and 2025 and operated by Korian Belgium. These homes are located respectively in Soignies (Wallonia), Heers, Lummen, Meldert, Diepenbeek, Heverlee, Halen, Lille and Hoeselt (Flanders). The facili...
Cession de 9 actifs immobiliers en Belgique
Cession de 9 actifs immobiliers en Belgique Communiqué de presse Cession de 9 actifs immobiliers en Belgique Paris, le 3 décembre 2025 Clariane (CLARI.PA – ISIN FR0010386334) : Clariane annonce aujourd’hui la cession d’un portefeuille d’actifs de santé situés en Belgique à Care Property Invest. Ce portefeuille se compose des murs de 9 maisons de repos et de soins développées entre 2010 et 2025 et opérées par Korian Belgium. Ces maisons sont situées respectivement à Soignies (Wallonie), Heers, Lummen, Meldert, Diepenbeek, Heverlee, Halen, Lille et Hoeselt (Flandres). Les établi...
GENFIT Announces Appointment of new Chief Medical Officer
GENFIT Announces Appointment of new Chief Medical Officer Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT’s clinical development plans and lead the Clinical (Operations and Strategy), Biometri...
GENFIT annonce la nomination d’un nouveau Directeur Médical
GENFIT annonce la nomination d’un nouveau Directeur Médical Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 27 novembre 2025 – GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la nomination du Dr. Pejvack Motlagh en tant que nouveau Directeur Médical de GENFIT. Membre du Comité Exécutif, le Dr Motlagh supervisera la stratégie, l’orientation et l’exécution des plans de développement clinique de GENFIT, et dirigera les équi...
Roche Holding AG: 1 director
A director at Roche Holding AG sold 2,000 shares at 315.250CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Emira Sagaama
- Emmanuel Matot
- Emira Sagaama
- Emmanuel Matot
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
GENFIT Reports Third Quarter 2025 Financial Information and Provides a...
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European markets Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients wit...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.